FDA understands that when a drug is in shortage, patients and health care professionals may look to compounded drugs as an option to get the medication they need.
Similar Posts
www.d-pharmacy.com – 711075 – 07/16/2025
Unapproved New Drugs/MisbrandedCoronavirus (COVID-19) Update: Daily Roundup April 13, 2020
Coronavirus (COVID-19) Update: Daily RoundupHintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
Learn more about recommendations for patients who are considering a Hintermann Series H3 TAR system or who have one; recommendations for health care providers.eCTD Submission Standards for eCTD v4.0 and Regional M1
A listing of the Implementation Guides, Specifications, and Documentation that support the FDA implementation for eCTD v4.0Resources for Biomarker Requestors
Information and resources for requestors about FDA’s Biomarker Qualification ProgramRationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
